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Abstract. 
 
NGF has been shown to support neuron sur-
vival by activating the transcription factor nuclear fac-
tor-
 
k
 
B (NF
 
k
 
B). We investigated the effect of NGF on
the expression of Bcl-xL, an anti–apoptotic Bcl-2 family
protein. Treatment of rat pheochromocytoma PC12
cells, human neuroblastoma SH-SY5Y cells, or primary
rat hippocampal neurons with NGF (0.1–10 ng/ml) in-
creased the expression of 
 
bcl-xL 
 
mRNA and protein.
Reporter gene analysis revealed a signiﬁcant increase
in NF
 
k
 
B activity after treatment with NGF that was as-
sociated with increased nuclear translocation of the ac-
tive NF
 
k
 
B p65 subunit. NGF-induced NF
 
k
 
B activity
and Bcl-xL expression were inhibited in cells overex-
pressing the NF
 
k
 
B inhibitor, I
 
k
 
B
 
a
 
. Unlike tumor ne-
crosis factor-
 
a
 
 (TNF-
 
a
 
), however, NGF-induced NF
 
k
 
B
activation occurred without signiﬁcant degradation of
I
 
k
 
Bs determined by Western blot analysis and time-
lapse imaging of neurons expressing green ﬂuorescent
protein–tagged I
 
k
 
B
 
a
 
. Moreover, in contrast to TNF-
 
a
 
,
NGF failed to phosphorylate I
 
k
 
B
 
a
 
 at serine residue 32,
but instead caused signiﬁcant tyrosine phosphorylation.
Overexpression of a Y42F mutant of I
 
k
 
B
 
a
 
 potently
suppressed NFG-, but not TNF-
 
a
 
–induced NF
 
k
 
B ac-
tivation. Conversely, overexpression of a dominant
negative mutant of TNF receptor-associated factor-6
blocked TNF-
 
a
 
–, but not NGF-induced NF
 
k
 
B activa-
tion. We conclude that NGF and TNF-
 
a
 
 induce differ-
ent signaling pathways in neurons to activate NF
 
k
 
B and
 
bcl-x 
 
gene expression.
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k
 
B
 
Introduction
 
Bcl-xL is an anti–apoptotic Bcl-2 family protein that is widely
expressed in the developing and adult nervous system (Boise
et al., 1993; Gonzalez-Garcia et al., 1995). Target disruption
 
of the 
 
bcl-x 
 
gene has demonstrated its importance for neu-
ronal survival. 
 
bcl-x
 
–deficient mice die in utero, exhibiting
pronounced cell death in both the peripheral and central ner-
vous system (Motoyama et al., 1995). 
 
bcl-x 
 
transcripts are al-
ternatively spliced into long and short forms. The protein
product of the long form (Bcl-xL) is a potent inhibitor of ap-
optosis, while the short form (Bcl-xS) accelerates apoptosis
(Boise et al., 1993). Bcl-xL is the Bcl-x form predominantly
expressed in neurons (Gonzalez-Garcia et al., 1995).
Little is known about the regulation of 
 
bcl-x
 
 gene ex-
pression in the nervous system. In blood cells, transcrip-
tion of the 
 
bcl-x 
 
gene is controlled by transcription factors,
signal transducer, and activator of transcription 5 and nu-
clear factor 
 
k
 
B (NF
 
k
 
B)
 
1
 
 (Dumon et al., 1999; Lee et al.,
1999; Socolovsky et al., 1999; Chen et al., 2000). Binding
sites for the active NF
 
k
 
B subunits p65/relA and c-rel have
been demonstrated by functional analysis of the 
 
bcl-x 
 
pro-
moter (Chen et al., 1999; Lee et al., 1999). Cytokines such
as tumor necrosis factor (TNF)-
 
a
 
 activate NF
 
k
 
B by induc-
ing the degradation of I
 
k
 
B proteins. These are cytosolic
proteins associated with NF
 
k
 
B subunits that function as
their inhibitors (Baeuerle and Baltimore, 1988). Degrada-
tion of I
 
k
 
B proteins has been shown to involve phosphory-
lation at serine residues, ubiquitination, and subsequent
degradation via the 26S proteasome complex (Palombella
et al., 1994; Brown et al., 1995; Traenckner et al., 1995).
We have previously shown that the cytokine transform-
ing growth factor-
 
b
 
1 also regulates the expression of the
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anti–apoptotic proteins Bcl-xL and Bcl-2 in primary neu-
ron cultures (Prehn et al., 1994, 1996). Likewise, the pro-
inflammatory cytokine TNF-
 
a
 
 has recently been shown to
increase Bcl-xL expression in neurons in an NF
 
k
 
B-depen-
dent manner (Tamatani et al., 1999). However, there is
growing evidence that NF
 
k
 
B activation is not only in-
volved in the nervous system response to injury or inflam-
mation, but is also required to support neuron survival
during development and in the adult nervous system. Acti-
vation of excitatory amino acid receptors (Kaltschmidt et
al., 1995) and release of neurotrophic factors may mediate
constitutive NF
 
k
 
B activity in neurons (Carter et al., 1996;
Maggirwar et al., 1998; Hamanoue et al., 1999; Middleton
et al., 2000). NGF in particular has been shown to increase
NF
 
k
 
B activity in various neuronal and nonneuronal popu-
lations (Wood, 1995; Carter et al., 1996; Taglialatela et al.,
1997; Ladiwala et al., 1998; Maggirwar et al., 1998; Yoon et
al., 1998; Hamanoue et al., 1999). The present study dem-
onstrates that NGF regulates the expression of Bcl-xL via
an NF
 
k
 
B-dependent pathway. Moreover, we demonstrate
that NGF-induced NF
 
k
 
B activation requires tyrosine
phosphorylation of the inhibitor I
 
k
 
B
 
a
 
, but occurs inde-
pendently of serine phosphorylation and degradation of
I
 
k
 
Bs via the proteasome.
 
Materials and Methods
 
Materials
 
Murine 2.5S NGF and recombinant human TNF-
 
a
 
 were from Pro-
mega. The proteasome inhibitors carbobenzoxyl-leucinyl-leucinyl-leucinal
(MG132) and lactacystin were purchased from Biomol. Sodium pervana-
date (Sigma-Aldrich) was prepared as described by Imbert et al. (1996). All
other chemicals came in molecular biological grade purity from Promega.
 
Cell Culture
 
Rat pheochromocytoma PC12 cells were grown in DME medium (Life
Technologies) supplemented with 10% horse serum (PAN Biotech), 5%
FCS (PAA) and the antibiotic mixture of 100 U/ml penicillin and 100 
 
m
 
g/
ml streptomycin (Life Technologies). Human neuroblastoma SH-SY5Y
cells were grown in RPMI 1640 medium (Life Technologies) supple-
mented with 10% FCS and the antibiotic mixture. Hippocampal neurons
were prepared from neonatal (P1) 344 rats (Fisher Scientific) as described
(Krohn et al., 1998). Cells were maintained in MEM supplemented with
10% NU
 
®
 
-Serum, 2% B-27 supplement (50
 
3
 
 concentrate), 2 mM 
 
L
 
-glu-
tamine, 20 mM 
 
D
 
-glucose, 26.2 mM sodium bicarbonate, and the antibiotic
mixture (Life Technologies). Hippocampal neurons were plated onto
poly-
 
L
 
-lysine–coated 35-mm Petri dishes (Becton Dickinson). Studies
were performed on 8–10-d-old cultures. Animal care followed official gov-
ernmental guidelines. Cultures were maintained at 37
 
8
 
C in a humidified
atmosphere of 95% air and 5% carbon dioxide.
 
Reverse Transcription PCR
 
Total RNA was extracted using the RNeasy Mini Kit (QIAGEN). Purity
of samples and RNA content were measured using a UV photometer
(Amersham Pharmacia Biotech). 1 
 
m
 
g of total RNA was reverse-tran-
scribed and amplified in a single reaction tube in a volume of 50 
 
m
 
l. The
reverse transcription (RT) reaction was performed at 42
 
8
 
C for 20 min in
the presence of oligo(dN) primers and Moloney murine leukemia virus re-
verse transcriptase (Amersham Pharmacia Biotech). After heat inactiva-
tion, specific oligonucleotide primer pairs for 
 
bcl-x
 
 and 
 
GAPDH
 
 (20 pmol
each; MWG) were added to the reaction mixture (1.5 mM MgCl
 
2
 
, 60 mM
KCl, 10 mM Tris-HCl, pH 9.0, 200 
 
m
 
M deoxynucleotides each and 2 U
Taq polymerase; Amersham Pharmacia Biotech). Primer pairs were based
on 
 
Mus musculus
 
 
 
bcl-x 
 
and 
 
Rattus norvegicus GAPDH
 
 sequences. The se-
quences of the primers were as follows: 
 
bcl-x
 
 sense primer, 5
 
9
 
-GGA GAG
CGT TCA GTG ATC-3
 
9
 
 and 
 
bcl-x 
 
antisense primer, 5
 
9
 
-CAA TGG TGG
CTG AAG AGA-3
 
9
 
; 
 
GAPDH
 
 sense primer, 5
 
9
 
-CTC GTG GTT CAC
ACC CAT-3
 
9
 
 and 
 
GAPDH
 
 antisense primer, 5
 
9
 
-GGC TGC CTT CTC
 
TTG TGA-3
 
9
 
. PCR was performed for 22 (
 
bcl-x
 
) or 15 (
 
GAPDH
 
) cycles
at 94
 
8
 
C for 30 s, 58
 
8
 
C for 60 s, and 72
 
8
 
C for 120 s using a Primus 25 ther-
mocycler (MWG). The amplified PCR products (expected size for 
 
bcl-xL
 
:
472 bp; expected size for 
 
GAPDH
 
: 355 bp) were separated on a 5% aga-
rose gel containing 0.1% ethidium bromide and visualized using a CCD
camera-based documentation system (MWG). Intensity of bands was ana-
lyzed using ONEDscan software (Scanalytics). The intensity of the
 
GAPDH
 
 amplification product served as internal control. Amplification
temperature and cycle number with respect to the linear range of the am-
plification process were empirically determined for each primer pair.
 
SDS-PAGE and Western Blotting
 
Cultures were rinsed with ice-cold PBS and lysed in TBS containing SDS,
glycerin, and protease inhibitors. Protein content was determined using
the BCA Micro Protein Assay kit (Pierce Chemical Co.) and samples
were supplemented with 2-mercaptoethanol and denaturated at 95
 
8
 
C for
5 min. An equal amount of protein (20–50 
 
m
 
g) was separated by
SDS-PAGE and blotted to nitrocellulose membranes (Protean BA 85;
Schleicher & Schuell). Equal loading of samples was confirmed by Pon-
ceau red staining. Nonspecific binding was blocked at room temperature
for 2 h by incubation in TBS containing 0.1% Tween-20, BSA, and nonfat
dry milk. The blots were then incubated over night at 4
 
8
 
C with the pri-
mary antibodies diluted in blocking buffer. Antibodies used were a rabbit
polyclonal anti–Bcl-x antibody (a gift from Prof. Craig B. Thompson, Uni-
versity of Pennsylvania, Philadelphia, PA) diluted 1:5,000, a mouse mono-
clonal anti–cyclooxygenase-2 (COX-2) antibody (clone 33; Transduction
Laboratories) diluted 1:2,000, a rabbit polyclonal antibody specific for
serine 32-phosphorylated I
 
k
 
B
 
a
 
 (P-Ser32-I
 
k
 
B
 
a
 
) (
 
N
 
ew England Biolabs,
Inc.) diluted 1:2,000, rabbit polyclonal antibodies recognizing I
 
k
 
B
 
a
 
 (
 
N
 
ew
England Biolabs, Inc., and sc-203; Santa Cruz Biotechnology, Inc.) diluted
1:2,000, a rabbit polyclonal antibody specific for I
 
kBb (sc-945; Santa Cruz
Biotechnology, Inc.) diluted 1:1,000, and a mouse monoclonal anti–
a-tubulin antibody (clone DM 1a; Sigma-Aldrich) diluted 1:2,000. After-
wards, membranes were washed and incubated with anti–mouse or –rabbit
IgG-HRP conjugate (1:5,000; Promega). Antibody-conjugated peroxidase
activity was visualized using the Super Signal chemiluminescence reagent
(Pierce Chemical Co.). Immunoblots were stripped in stripping buffer
(2% SDS, 62.5 mM Tris-HCl, 100 mM 2-mercaptoethanol, pH 6.8) for 20
min at 608C, washed, and reprobed.
Immunocytochemistry and Visualization of the Active 
p65 NFkB Subunit 
After stimulation with NGF, cells were washed and fixed with 4%
paraformaldehyde in PBS at 378C for 20 min. Fixed cells were permeabi-
lized by treatment with ice-cold 0.1% Triton X-100 in PBS. Nonspecific
antibody binding was blocked by PBS, pH 7.4, containing 2% nonfat dry
milk, 2% BSA, and 0.1% Tween 20 for 1 h at room temperature. The ac-
tive p65 NFkB subunit was visualized using a mouse monoclonal antibody
(clone 12H11; Roche) that recognizes an epitope overlapping the nuclear
location signal of the p65 NFkB subunit (Zabel et al., 1993; Kaltschmidt et
al., 1995). The antibody was diluted 1:100 in blocking buffer and incubated
overnight at 48C. Afterwards, cells were washed with PBS and labeled
with biotin-conjugated anti–mouse IgG (1:1,000; Vector Laboratories) for
1 h at room temperature. After being washed, cells were incubated for 30
min in a mixture of avidin and biotinylated HRP reagent (Vectastain Elite
ABC Kit; Vector Laboratories). Staining procedure was performed using
DAB as chromogen (1 mg/ml) in the presence of Ni21 and hydrogen per-
oxide. After 8–10 min, the chromogen was washed out and cells were ob-
served in transmitted light using an Eclipse TE300 inverted microscope
(Nikon). Digital images of equal exposure were acquired with a SPOT-2
camera (Diagnostic Instruments).
Analysis of NFkB Reporter Gene Activity 
PC12 cells were seeded on poly-L-lysine coated 24-well plates at a density
of 104 cells per well. Cells were then transfected with 0.75 mg of a plasmid
containing four tandem repeats of the k enhancer element fused to the her-
pes simplex virus thymidine kinase promoter upstream of the coding se-
quence for a secreted form of human placental alkaline phosphatase
(SEAP) (pNFkB-SEAP; CLONTECH Laboratories, Inc.). In the experi-
ment shown in Fig. 3 (below), PC12 cultures were cotransfected with 0.25
mg of a human wild-type IkBa expression plasmid (pIkBa) controlled by
the cytomegalovirus promoter or control DNA of similar kilobase size. The
IkBa expression plasmid was originally generated and published by Brock-
man et al. (1995). In the experiment shown in Fig. 5 (below), PC12 cellsBui et al. Nerve Growth Factor-induced NFkB Activation 755
were cotransfected with 0.05 mg of a wild-type IkBa or mutant IkBa Y42F
pcDNA expression plasmid (Imbert et al., 1996). In the experiments shown
in Fig. 6 (below), PC12 cells were cotransfected with 0.01 or 0.05 mg of a
dominant-negative TNF receptor-associated factor-6 (TRAF6 dn) expres-
sion plasmid (a gift from Dr. H. Wajant, University of Stuttgart, Stuttgart,
Germany). For the generation of the dominant-negative mutant, a cDNA
fragment comprising human TRAF6 (253–522) with a 59 BamHI site and a
39 NotI site was cloned into expression vector pcDNA3.1 (Invitrogen).
Cells were transfected using polyethylenimine or the Lipofectamine trans-
fection reagent (Life Technologies). 24–48 h after transfection, basal SEAP
in the culture medium was washed out and fresh media containing NGF,
TNF-a, or vehicle was added. The medium was collected after 6 and 24 h
and a fluorescence SEAP assay was performed (Great EscaAPe Fluores-
cence Detection Kit; CLONTECH Laboratories, Inc.) using 4-methylum-
belliferyl phosphate as substrate for SEAP. Fluorescence intensity was
measured using a fluorescence plate reader (HTSoft 7000; PerkinElmer)
(360 nm excitation, 465 nm emission). Each set of experiments included
cultures transfected with a plasmid identical to the reporter construct but
lacking the k enhancer element as negative control for background signals.
As control for transfection efficiency, cultures were cotransfected with a
pSV–b-galactosidase plasmid, and NFkB reporter gene activity was nor-
malized to b-galactosidase expression.
Overexpression of IkBa and
Immunofluorescence Analysis
PC12 cells were plated onto poly-L-lysine–coated eight-well tissue culture
slides (Becton Dickinson) at a density of 104 cells per well. Cultures were
then cotransfected with 0.25 mg of pIkBa or control plasmid DNA, as well
as a plasmid encoding enhanced green fluorescent protein (EGFP) as
transfection control. After 72 h recovery, cells were exposed to NGF,
TNF-a, or vehicle for 6 h, fixed, and permeabilized as described above.
After blocking for 1 h at room temperature, the specimens were incubated
at 48C overnight with the rabbit polyclonal Bcl-x antibody diluted 1:500 in
blocking buffer. After washing, biotin-conjugated anti–rabbit IgG (1:
1,000; Vector Laboratories) was added for 1 h at room temperature, fol-
lowed by a streptavidin–Texas red conjugate (1 mg/ml, 20 min; Molecular
Probes). Texas red fluorescence was observed using the Eclipse TE300 in-
verted microscope and a 403 oil immersion objective (Nikon) with the
following optics: 510–560 nm excitation, 575 nm dichroic mirror, .590 nm
emission. For the observation of the EGFP fluorescence, the following op-
tics were used: 465–495 nm excitation, 505 nm dichroic mirror, 515–555
nm emission. Digital images of equal exposure were acquired with the
SPOT-2 camera using Metamorph software (Universal Imaging Corp.).
For quantification of Bcl-xL immunoreactivity, average pixel intensity of
the Texas red fluorescence of single cells expressing EGFP was measured
using Metamorph software. Background fluorescence intensities of the
specimen were substracted from the values.
Immunoprecipitation
After exposure to NGF, sodium pervanadate, or vehicle, PC12 cells were
rinsed with PBS and lysed in buffer containing (mM): 50 Tris-HCl, pH 7.5,
0.5% NP-40, 10% glycerol, 250 NaCl, 5 EDTA, 50 NaF, 0.5 Na3VO4, 10
b-glycerophosphate, and the protease inhibitors PMSF (0.5 mM), leupeptin,
and aprotinin (5 mg/ml). Protein content was determined and 250 mg pro-
tein extract was immunoprecipitated using a mouse monoclonal antibody
(0.5 mg) recognizing tyrosine-phosphorylated proteins (sc-508; Santa Cruz
Biotechnology, Inc.). As negative control, lysates were immunoprecipi-
tated using mouse control IgG (Santa Cruz Biotechnology, Inc.). Samples
were rotated overnight at 48C and the antibody–protein complexes were
precipitated for 2 h at 48C using protein agarose A/G plus (Santa Cruz Bio-
technology, Inc.). The beads were centrifuged and washed four times. Sam-
ples were supplemented with 2-mercaptoethanol and denatured at 958C for
2 min. Immunoprecipitated proteins were subjected to 10% SDS-PAGE,
blotted, and detected using a rabbit polyclonal anti–IkBa antibody (sc-203;
Santa Cruz Biotechnology, Inc.), diluted 1:2,000. For immunoprecipitation
control, the supernatants were collected and aliquots were subjected to
SDS-PAGE. IkBa protein was not detectable in the supernatants.
Time-Lapse Imaging of Neurons
Expressing IkBa-EGFP 
PC12 cells were plated at a density of 104 cells on 35-mm glass-bottom
dishes (Willco BV) coated with poly-L-lysine. Cultures were then trans-
fected with 0.75 mg of a plasmid encoding an IkBa-EGFP fusion protein
(pIkBa-EGFP; CLONTECH Laboratories, Inc.) or a plasmid expressing
EGFP. After 24-h recovery, EGFP fluorescence was observed using an
Eclipse TE 300 inverted microscope and a 403 oil immersion objective
equipped with the appropriate filter set (465–495 nm excitation, 505 nm
dichroic mirror, 515–555 nm emission). Time-lapse digital images of equal
exposure were acquired with the SPOT-2 camera using Spot software ver-
sion 2.2.1. After acquiring the first image, cells transfected with pIkBa-
EGFP were incubated with NGF, TNF-a, or vehicle directly on the stage.
In control experiments, cultures transfected with EGFP were exposed to
TNF-a. The incubation medium was enriched with 10 mM Hepes and
thoroughly mixed to ensure a proper distribution of the agents. Images
were analyzed using Metamorph software. Fluorescence data are given as
change in average pixel intensity compared with the first image. Back-
ground fluorescence of each image was subtracted from the values.
Figure 1. NGF increases neuronal Bcl-xL expression. (a, Top)
Rat pheochromocytoma PC12 cells were treated with NGF (10
ng/ml) or vehicle (Con) for the indicated period of time and ex-
pression of bcl-xL and GAPDH (internal control) mRNA was
determined by RT-PCR. (Bottom) Intensity of bcl-xL bands rel-
ative to GAPDH plotted against the respective time points from
the same experiment. The experiment was performed twice with
similar results. Rat PC12 cells (b), rat hippocampal neuron cul-
tures (c) and human neuroblastoma SH-SY5Y cells (d) were ex-
posed to NGF or vehicle. After 6 h, cytosolic protein extracts
were subjected to 15% SDS-PAGE. Immunodetection of Bcl-xL
was performed using a rabbit polyclonal antibody specific for
Bcl-x. Experiments were performed in duplicate or triplicate with
comparable results.The Journal of Cell Biology, Volume 152, 2001 756
Statistics
Data are presented as means 6 SEM. For statistical comparison, one-way
analysis of variance followed by LSD test were employed. Kruskal-Wallis
H test followed by Bonferroni-corrected Mann-Whitney U test were used
for statistical evaluation of nonparametric data. P , 0.05 was considered
to be statistically significant.
Results
Nerve Growth Factor Upregulates Neuronal bcl-xL 
mRNA and Bcl-xL Protein Expression
To investigate the effect of NGF on neuronal bcl-xL
mRNA expression, PC12 cells were treated with 10 ng/ml
NGF for time periods of 1–8 h. Total RNA was isolated
and subjected to semiquantitative RT-PCR using bcl-x
and  GAPDH-specific oligonucleotide primers. bcl-xL
mRNA expression increased in the PC12 cells after 2 h of
NGF treatment, remained at a high level after 4 h, and
then declined after 8 h (Fig. 1 a). In agreement with the
RT-PCR data, we detected increased Bcl-xL protein ex-
pression in PC12 cells treated with NGF (Fig. 1 b). Inter-
estingly, a strong response was already observed in cul-
tures treated with NGF concentrations as low as 0.1 and 1
ng/ml. The Bcl-xL level of cultures treated with very high
NGF concentrations (50–100 ng/ml) declined again (data
not shown).
NGF also increased Bcl-xL protein expression in pri-
mary rat hippocampal neurons, with maximal effects again
seen after treatment with 1 ng/ml NGF (Fig. 1 c). bcl-xL
mRNA and Bcl-xL protein expression was also increased
in human neuroblastoma SH-SY5Y cells treated with
NGF (Fig. 1 d and data not shown).
Nerve Growth Factor Activates NFkB
NFkB binding sequences have been identified in the pro-
moter region of the human and murine bcl-x gene (Chen
et al., 1999; Lee et al., 1999). To obtain evidence for in-
creased NFkB activity after treatment with NGF, we per-
formed an immunocytochemical analysis in PC12 and SH-
SY5Y cells using a monoclonal antibody raised against an
epitope overlapping the nuclear localization signal of the
NFkB p65 subunit. This epitope is normally inaccessible
because of binding of the endogenous inhibitor IkB (Za-
bel et al., 1993; Kaltschmidt et al., 1995). Dissociation of
the inhibitor exposes the nuclear localization signal of p65,
enabling it to be imported into the nucleus and to activate
transcription (Baeuerle and Baltimore, 1988). Treatment
of PC12 cells with NGF induced a strong increase in the
immunoreactivity of the active NFkB subunit p65 in the
nucleus with maximal effects observed at a concentration
of 1 ng/ml (Fig. 2, a and b). Treatment of human SH-SY5Y
neuroblastoma cells with NGF also increased the immu-
noreactivity of the active p65 subunit, both in the cyto-
plasm and in the nucleus (Fig. 2, c and d).
To provide direct evidence for increased NFkB activity
after NGF treatment, PC12 cells were transfected with a
reporter plasmid containing four tandem repeats of the k
enhancer element fused to the herpes simplex virus thymi-
dine kinase promoter upstream of the coding sequence for
the reporter gene SEAP. Treatment of PC12 cells with 1
ng/ml NGF induced NFkB activity to an extent compara-
ble with that induced by TNF-a (10 ng/ml), a cytokine that
is known to increase NFkB activity in neurons (Barger et
al., 1995) and that served as a positive control (Fig. 2 e).
Increased NFkB activity could also be detected by re-
Figure 2. NGF activates NFkB.
Immunocytochemical detec-
tion of the active p65 subunit.
Rat pheochromocytoma PC12
cells were treated with vehicle
(a) or 1 ng/ml NGF (b) for 4 h,
fixed, and probed with a mouse
monoclonal antibody that rec-
ognizes an epitope overlapping
the nuclear translocation signal
of the p65 NFkB subunit. Note
the increased active p65 immu-
noreactivity in the nuclei. Hu-
man neuroblastoma SH-SY5Y
cells were treated with vehicle
(c) or 10 ng/ml NGF (d) for 4 h
and analyzed as described
above. Note the increased ac-
tive p65 immunoreactivity in
the nuclei and the cytoplasm.
Scale bar, 25 mm. (e) NF-kB ac-
tivity determined in PC12 cells
by reporter gene assay. Cells
were transfected with a re-
porter plasmid (pNFkB-
SEAP). 24 h after transfection,
cultures were treated with NGF (1 ng/ml), TNF-a (10 ng/ml), or vehicle. Culture medium was collected after 6 and 24 h of treatment
and a fluorescent SEAP assay was performed. Data are means 6 SEM from n 5 14–15 cultures in three separate experiments. (f)
Western blot analysis of the NFkB-regulated gene product COX-2 in PC12 cells treated for 6 h with vehicle, NGF, or TNF-a.Bui et al. Nerve Growth Factor-induced NFkB Activation 757
porter gene analysis in human SH-SY5Y neuroblastoma
cells exposed to NGF (data not shown).
Finally, evidence for increased NFkB activity after NGF
treatment was provided by determining the expression of the
NFkB target gene COX-2 (Yamamoto et al., 1995). Expres-
sion of COX-2 protein increased after treatment with NGF
to a similar extent as after treatment with TNF-a (Fig. 2 f).
NGF-Induced NFkB Activity and Bcl-xL Expression Is 
Inhibited in PC12 Cells Overexpressing IkBa
To investigate the requirement of NFkB activation for NGF-
induced Bcl-xL expression, PC12 cells were transiently trans-
fected with a plasmid encoding the NFkB inhibitor IkBa or
control DNA. Overexpression of IkBa reduced both NGF-
and TNF-a–induced NFkB activity analyzed by the reporter
gene assay (Fig. 3 a). We next analyzed Bcl-xL protein ex-
pression in IkBa-overexpressing PC12 cells cotransfected
with EGFP as transfection control. In agreement with our
observations described above (Fig. 1), Bcl-xL immunofluo-
rescence increased significantly after a 6-h treatment with
NGF (1 ng/ml) in cultures transfected with control DNA
(Fig. 3, b and c). Increased Bcl-xL expression was also ob-
served in control-transfected PC12 cells exposed to TNF-a
(10 ng/ml). Overexpression of IkBa did not significantly alter
the level of Bcl-xL expression in vehicle-treated control cells
(ANOVA and LSD test; P 5 0.131). Interestingly, however,
NGF and TNF-a failed to increase neuronal Bcl-xL expres-
sion in cells overexpressing the inhibitor.
TNF-a, but Not NGF Induces Rapid Degradation
of IkBs
IkB degradation has been shown to be required for activa-
tion of NFkB by proinflammatory cytokines (Palombella
et al., 1994). We therefore determined a time course of
IkBa protein degradation in PC12 cells exposed to TNF-a
or NGF (Fig. 4, a and b). TNF-a induced significant IkBa
degradation, starting 10 min after the onset of treatment.
In contrast, treatment with NGF for up to 8 h failed to in-
duce significant degradation of IkBa. NGF also failed to
trigger the degradation of a second NFkB inhibitory pro-
tein, IkBb (Thompson et al., 1995). In contrast, IkBb deg-
radation also occurred in TNF-a–treated cultures, albeit
with slower kinetics.
To analyze IkBa degradation in response to NGF and
TNF-a on the single cell level, PC12 cells were transfected
with a plasmid encoding EGFP-tagged IkBa. The fusion
protein has been previously shown to be degraded after
serine phosphorylation with kinetics similar to IkBa, re-
sulting in a decrease in cellular IkBa-EGFP fluorescence
(Li et al., 1999). Treatment of IkBa-EGFP–transfected
6 h and fixed. Bcl-xL expression was determined by immunofluo-
rescence analysis using the Bcl-x antibody followed by biotin-
ylated secondary antibody and streptavidin Texas red conjugate.
Bcl-xL immunofluorescence was quantified by measuring the av-
erage pixel intensity of the Texas red fluorescence of single cells
expressing EGFP. Data are mean 6 SEM from n 5 17–70 cells in
two to three separate cultures per treatment. Experiments were
repeated two times with similar results. Scale bar, 10 mm.
Figure 3. IkBa overexpression inhibits NGF-induced NFkB ac-
tivity and Bcl-xL expression. (a) PC12 cells were transiently
cotransfected with a IkBa expression vector or control plasmid
DNA (control DNA) and the reporter plasmid pNFkB-SEAP. 48 h
after transfection, cultures were treated with NGF (1 ng/ml),
TNF-a (10 ng/ml), or vehicle. Culture media were collected after
6 h and a fluorescence SEAP assay was performed. Data are
mean 6 SEM from n 5 5–6 cultures per treatment. A duplicate
experiment yielded comparable results. (b and c) PC12 cells were
cotransfected with pCMV-IkBa or control plasmid and pCMV-
EGFP as transfection control. After a 72-h recovery, cultures
were exposed to NGF (1 ng/ml), TNF-a (10 ng/ml), or vehicle forThe Journal of Cell Biology, Volume 152, 2001 758
cells with TNF-a induced a significant decrease in fluores-
cence after 10 min of exposure (Fig. 4 c). In contrast, cellu-
lar IkBa-EGFP fluorescence did not decrease in cells
treated with NGF or vehicle monitored up to 2 h. As a
control for specificity of the TNF-a induced decrease in
IkBa-EGFP fluorescence, PC12 cells were transfected
with a plasmid encoding EGFP. Treatment with TNF-a
did not induce a decrease in cellular EGFP fluorescence.
IkBa Is Not Phosphorylated at Serine 32 after
NGF Stimulation
IkBa has been shown to be phosphorylated at serine 32
and 36 residues after treatment with NFkB-inducing cy-
tokines (Brown et al., 1995; Traenckner et al., 1995). To in-
vestigate serine phosphorylation of IkBa after treatment
with NGF, we performed immunoblot experiments using
an antibody specific for P-Ser32-IkBa. While treatment of
PC12 cells with TNF-a induced an increase in P-Ser32-
IkBa after 10 min of exposure with maximal effects seen
after 30 min, NGF failed to induce any significant increase
in P-Ser32-IkBa up to 8 h after its addition to the cultures
(Fig. 5 a). At this time point, NGF had already caused a
pronounced increase in NFkB activity (Fig. 2). The (lack
of) effect was independent of the NGF concentration used,
as similar results were obtained in cultures treated with 10
ng/ml NGF (data not shown). TNF-a–, but not NGF-in-
duced serine 32 phosphorylation of IkBa was also ob-
served in human SH-SY5Y neuroblastoma cells (Fig. 5 b).
Tyrosine Phosphorylation of IkBa in NGF-stimulated 
PC12 Cells
Phosphorylation of IkBa at tyrosine residue 42 has been
shown to activate NFkB without requiring IkBa degrada-
tion via the proteasome (Imbert et al., 1996; Béraud et al.,
1999). We performed immunoprecipitation experiments to
analyze tyrosine phosphorylation of IkBa. PC12 cells were
exposed to NGF (10 ng/ml) or sodium pervanadate (200
mM) as a positive control, and cytosolic extracts were sub-
jected to immunoprecipitation using a murine monoclonal
antibody raised against tyrosine-phosphorylated proteins.
As a negative control, cell lysates were immunoprecipi-
tated with mouse control IgG. Detection of immunopre-
cipitated proteins by SDS-PAGE and Western blot analy-
sis using an IkBa antibody demonstrated that sodium
pervanadate induced significant tyrosine phosphorylation
of IkBa (Fig. 5 c). Treatment with NGF also induced
strong tyrosine phosphorylation of IkBa after 120 min of
treatment. Tyrosine-phosphorylated IkBa could also be
detected in response to TNF-a (data not shown), presum-
ably a consequence of the known ability of NFkB-activat-
ing cytokines to stimulate NGF synthesis in neural cells
(Hattori et al., 1993; Friedman et al., 1996).
To investigate whether phosphorylation of IkBa at
tyrosine residue 42 mediated NGF-induced NFkB acti-
vation, cells were transfected with a plasmid encoding
wild-type IkBa or a mutant IkBa (Y42F), which has
been shown to block NFkB activation after tyrosine
phosphorylation of IkBa (Imbert et al., 1996). We ti-
trated down the amount of wild-type IkBa plasmid
DNA to a concentration at which NGF and TNF-a were
still able to elicit significant NFkB activation (Fig. 5 d).
Figure 4. TNF-a, but not NGF induces degradation of IkBs a
and b. Degradation of IkBa and IkBb in PC12 cells treated with
(a) TNF-a (10 ng/ml) or (b) NGF (1 ng/ml) for the indicated pe-
riod of time. 50 mg protein extract were separated on 12% SDS-
PAGE, blotted onto nitrocellulose membrane, and IkBa or b
was detected using rabbit polyclonal antibodies. Membranes
were stripped and probed with an a-tubulin mouse monoclonal
antibody as control for equal sample loading. Experiments were
performed in triplicate with similar results. (c) PC12 cells were
transiently transfected with plasmids encoding an IkBa-EGFP
fusion protein or EGFP. After 24–48 h recovery, cells were
treated with vehicle, NGF (1 ng/ml), or TNF-a (10 ng/ml). Cells
overexpressing EGFP were exposed to TNF-a (EGFP 1 TNF-a).
Quantification of changes in EGFP fluorescence after a 10-min
exposure to vehicle, NGF, or TNF-a. Data are mean 6 SEM
from n 5 4 separate transfection experiments per treatment.
Data are given as change in average pixel intensities compared
with the first image.Bui et al. Nerve Growth Factor-induced NFkB Activation 759
Transfection with the same concentration of plasmid
DNA encoding mutant Y42F IkBa led to a complete in-
hibition of NGF-induced NFkB activation. In contrast,
TNF-a–induced NFkB activation was not inhibited by
the IkBa Y42F mutant.
Figure 5. NGF induces tyrosine phosphorylation of IkBa. (a) PC12
cells were exposed to TNF-a (10 ng/ml) or NGF (1 ng/ml) for the in-
dicated period of time. An equal amount of protein was subjected to
12% SDS-PAGE and blotted onto nitrocellulose membrane. Immu-
nodetection was performed using a rabbit polyclonal antibody spe-
cific for P-Ser32-IkBa. Protein samples were identical to those
shown in Fig. 4, a and b. The experiment was performed in triplicate
with similar results. (b) SH-SY5Y cells were stimulated with the in-
dicated concentrations of NGF, TNF-a, or vehicle for 6 h. Cells were
collected and lysed, and total protein amount was determined. After
separation on 12.5% SDS-PAGE, the P-Ser32-IkBa antibody was
used to detect serine 32-phosphorylation (top). Afterwards, mem-
branes were stripped and probed with a rabbit polyclonal antibodies
recognizing IkBa (bottom). (c) PC12 cells were stimulated with
NGF (10 ng/ml), sodium pervanadate (pV; 200 mM), or vehicle for
the indicated period of time. Cells were lysed and 250 mg protein
was immunoprecipitated using a mouse monoclonal antibody raised
against tyrosine phosphorylated proteins (p-Tyr) or mouse control
IgG (IgG). After precipitation and denaturation of the antibody–
protein complex, samples were subjected to 10% SDS-PAGE and
blotted. Immunodetection was performed using a rabbit polyclonal
antibody specific for IkBa. Experiments were performed three
times with similar results. (d) Effect of overexpression of wild-type
and Y42F-mutated IkBa on NGF-induced NFkB activation. PC12
cells were cotransfected with the IkBa-encoding plasmids and the
reporter plasmid pNFkB-SEAP. 24 h after transfection, cells were
stimulated with NGF (1 ng/ml), TNF-a (10 ng/ml), or vehicle. Cul-
ture medium was collected after 6 h and a fluorescence SEAP assay
was performed. Data are mean 6 SEM from n 5 18 cultures in
three separate experiments.
Figure 6. Overexpression of dominant-negative TRAF-6 inhibits
TNF-a, but not NGF-induced NFkB activation. PC12 cells were
cotransfected with (a) 0.01 or (b) 0.05 mg of a TRAF6 dn expres-
sion vector or control plasmid DNA (control DNA) and the re-
porter construct pNFkB-SEAP. 24 h after transfection, cells were
stimulated with (a) TNF-a (10 ng/ml), (b) NGF (1 ng/ml), or ve-
hicle for 6 h. Culture media were collected and a fluorescence
SEAP assay was performed. Data are mean 6 SEM from n 5 5–6
cultures per treatment.The Journal of Cell Biology, Volume 152, 2001 760
Overexpression of a Dominant-Negative Mutant of 
TRAF-6 Inhibits TNF-a-, but Not NGF-induced
NFkB Activation
TRAF proteins are proximal signaling components re-
quired for TNF-a–induced NFkB activation (Rothe et
al., 1995). In a similar pathway, selective activation of
NFkB via p75 NGF receptors has been shown to involve
the association of TRAF6 to the receptor complex
(Khursigara et al., 1999; Ye et al., 1999; Foehr et al.,
2000). To demonstrate differential activation pathways
for TNF-a and NGF upstream of IkB phosphorylation,
we transiently expressed TRAF6 dn in PC12 cells (Fig.
6). Overexpression of TRAF6 dn potently inhibited
TNF-a–, but failed to inhibit NGF-induced NFkB activa-
tion.
NGF Induces Bcl-xL Expression in the Presence of 
Proteasome Inhibitors
NFkB activation via tyrosine phosphorylation of IkBa oc-
curs independently of IkBa ubiquitination and degrada-
tion via the proteasome (Imbert et al., 1996; Béraud et al.,
1999). To demonstrate that NGF was able to induce the
expression of NFkB-target genes independent of the pro-
teasome, we treated PC12 cells with two proteasome in-
hibitors, MG132 and lactacystin. Treatment with these in-
hibitors significantly reduced basal Bcl-xL expression in
PC12 cells (Fig. 7 a). As expected, treatment with NGF
was able to induce a strong increase in Bcl-xL expression
in the presence of the two inhibitors. Semiquantitative
RT-PCR revealed that NGF also increased neuronal bcl-
xL mRNA expression in cultures treated with proteasome
inhibitors (data not shown). Similarly, NGF increased the
expression of the NFkB target gene COX-2 in the pres-
ence of the proteasome inhibitor lactacystin (Fig. 7 b). In
contrast, treatment with lactacystin inhibited TNF-a–induced
Bcl-xL expression (Fig. 7 c).
Discussion
In the present study, we have demonstrated that NGF in-
duced the expression of the antiapoptotic protein Bcl-xL
in rat pheochromocytoma PC12 cells, human neuroblas-
toma SH-SY5Y cells, and primary rat hippocampal neu-
rons. Upregulation of bcl-x expression in response to NGF
has previously been observed in PC12 cells (Rong et al.,
1999; Foehr et al., 2000). Bcl-xL is required for the survival
of many peripheral and central neurons during develop-
ment, and has been shown to protect cells against a variety
of metabolic and toxic challenges such as trophic factor
withdrawal, oxidative stress, and hypoxia/ischemia (Boise
et al., 1993; Gonzalez-Garcia et al., 1995; Parsadanian et
al., 1998; Wiessner et al., 1999). NGF-induced Bcl-xL ex-
pression was inhibited in cells overexpressing the NFkB
inhibitor IkBa, indicating that NFkB activation was re-
quired for the upregulation of neuronal Bcl-xL expression
(Tamatani et al., 1999; Foehr et al., 2000). NGF also in-
creases the expression of Bcl-2 (Riccio et al., 1999), an an-
tiapoptotic protein closely related to Bcl-xL. Interestingly,
upregulation of Bcl-2 by NGF involves a CREB-depen-
dent transcriptional pathway (Liu et al., 1999; Riccio et al.,
1999). It is remarkable that NGF has the capacity to in-
crease the neuronal expression of two antiapoptotic pro-
teins with a similar mechanism of action, via two separate
transcriptional pathways. Activation of NFkB has also
been shown to increase the expression of inhibitor of ap-
optosis proteins (You et al., 1997; Stehlik et al., 1998).
These proteins have been identified as NGF-inducible tar-
get genes in chicken (Wiese et al., 1999), and function as
endogenous inhibitors of a family of proapoptotic cysteine
proteases, the caspases. It is therefore conceivable that the
survival-promoting effects of NGF are largely mediated
via an increased transcription of genes that are conserved
components of the apoptotic cell death machinery.
TNFs-a and -b, as well as cytokines of the interleukin-6
family have also been shown to increase NFkB activity in
Figure 7. Proteasome inhibition and NGF-induced Bcl-xL ex-
pression. (a) PC12 cells were pretreated with MG132 (10 mM),
lactacystin (Lacta; 20 mM), or vehicle for 30 min followed by a 6-h
stimulation with NGF (10 ng/ml) or vehicle. Cells were lysed
and 30 mg protein was subjected to 15% SDS-PAGE. Separated
proteins were blotted onto nitrocellulose membrane and Bcl-xL
expression was immunodetected using the a- Bcl-x antibody
(top). (b) Immunodetection of the NFkB-inducible gene product
COX-2 after pretreatment with lactacystin (Lacta; 20 mM) or ve-
hicle for 30 min followed by a treatment with NGF (10 ng/ml) for
6 h (top). (c) Bcl-xL protein expression in PC12 cells after pre-
treatment with lactacystin (Lacta; 20 mM) or vehicle for 30 min
followed by a stimulation with TNF-a (10 ng/ml) or vehicle for 6 h
(top). a-Tubulin mouse monoclonal antibody served as control
for detection of equal sample loading after stripping of mem-
branes (bottom).Bui et al. Nerve Growth Factor-induced NFkB Activation 761
cultured neurons (Barger et al., 1995; Middleton et al.,
2000). In the present study, treatment with NGF induced a
significant NFkB activity comparable with that induced by
TNF-a. Of note, our data demonstrate that the pathway ac-
tivated by NGF is distinct from that activated by TNF-a.
NFkB activity induced by TNF-a involves serine phosphor-
ylation of IkB proteins via IkB kinases (DiDonato et al.,
1997; Malinin et al., 1997; Mercurio et al., 1997), resulting
in the subsequent ubiquitination and degradation by the
proteasome. Both events, serine phosphorylation of IkBa
and degradation of IkB proteins, could be clearly detected
in response to TNF-a. In contrast, NGF did not lead to sig-
nificant serine phosphorylation, but instead induced ty-
rosine phosphorylation of IkBa. The effect of NGF was
mimicked by pervanadate, an agent that activates NF-kB
via tyrosine phosphorylation of IkBa at residue 42 (Imbert
et al., 1996; Singh et al., 1996). Importantly, overexpression
of a Y42F mutant of IkBa potently suppressed NFG-, but
not TNF-a–induced NFkB activation. This suggests that (a)
tyrosine phosphorylation at this site is required for NGF-
induced NFkB activation, and (b) TNF-a–induced serine
phosphorylation of IkBa is sufficient to activate NFkB.
Phosphorylation of IkBa on tyrosine residue 42 has also
been observed pathophysiologically in response to hy-
poxia/reoxygenation (Koong et al., 1994). However, our
report is the first demonstration of ligand-induced tyrosine
phosphorylation of IkBa. Tyrosine-phosphorylated IkBa
has been reported to have a half life similar to that of non-
phosphorylated IkBa, and activation of NFkB may occur
by a degradation-independent dissociation of the inhibitor
from the p65 subunit (Imbert et al., 1996; Béraud et al.,
1999). Cultures treated with NGF indeed failed to provide
strong evidence for IkBa degradation. We cannot fully ex-
clude the absence of IkBa degradation in light of the rapid
turnover of IkBa in cultured neurons and the fact that
IkBa is rapidly resynthesized as a consequence of NFkB
activation (Maggirwar et al., 1998). Interestingly, however,
NGF induced Bcl-xL expression in the presence of protea-
some inhibitors, suggesting that serine phosphorylation,
ubiquitination, and degradation via the proteasome were
in fact not involved in NGF-induced NFkB activation.
NGF activates the PI3-kinase/Akt kinase pathway in neu-
rons (Yao and Cooper, 1995; Crowder and Freeman, 1998;
Xue et al., 2000). Béraud et al. (1999) have recently dem-
onstrated that both the regulatory p85 and the catalytic
p110 subunit of PI3-kinase are involved in NFkB activa-
tion after tyrosine phosphorylation of IkBa. The authors
observed an interaction of the COOH-terminal SH2 do-
main of p85 with tyrosine phosphorylated IkBa. It remains
to be shown whether this interaction induces a dissociation
of the IkBa/NFkB complex in the absence of IkBa degra-
dation. However, NGF-induced PI3-kinase/Akt activation
may also stimulate additional regulatory steps in NFkB-
dependent gene transcription; for example, by increasing
the transactivation potential of NFkB (Madrid et al., 2000).
The rat pheochromocytoma PC12 and the human neuro-
blastoma SH-SY5Y cells used in the present study express
both the trkA and p75 neurotrophin receptors (our unpub-
lished data). Submaximal NGF concentrations (0.1–1 ng/
ml) were sufficient to induce NFkB activity and Bcl-xL ex-
pression, suggesting that the p75 receptor may play a role
in potentiating the effect of NGF transduced via the trkA
receptor (Davies et al., 1993). Interestingly, the p75 recep-
tor has also been shown to signal NGF-induced NF-kB ac-
tivity in the absence of trkA receptors (Carter et al., 1996;
Ladiwala et al., 1998; Yoon et al., 1998). Moreover, NGF-
induced NFkB activation via selective activation of p75 in
the trkA-deficient Schwann cell line RN22 has been shown
to involve both serine phosphorylation and degradation of
IkBa (Gentry et al., 2000). It is conceivable that, in the ab-
sence of trkA, NGF activates NF-kB via a pathway resem-
bling that induced by TNF-a. In support of this concept,
the p75 receptor also associates with TRAF proteins
(Khursigara et al., 1999; Ye et al., 1999), adaptor proteins
that are required for TNF-a–induced NFkB activation
(Rothe et al., 1995). In the present study, TNF-a–induced
NFkB activation in PC12 cells was potently inhibited by
overexpression of a dominant-negative mutant of TRAF6,
while NGF-induced NFkB activation was not suppressed.
Because selective activation of NFkB via p75 NGF recep-
tors has been shown to be sensitive to overexpression of
dominant-negative TRAF6 (Khursigara et al., 1999; Foehr
et al., 2000), NGF-induced NFkB activation in PC12 cells
primarily involved a signal transduction pathway down-
stream of trkA receptors. Nevertheless, the extent of serine
and tyrosine phosphorylation of IkBs as well as the extent
of IkB degradation via the proteasome in response to NGF
may vary in different cell types depending on the relative
contribution of the signal transduction pathways activated
by p75 and trkA receptors (Hamanoue et al., 1999).
There is also evidence for a cross talk between Akt and
IkB kinase activation (Ozes et al., 1999; Romashkova and
Makarov, 1999; Foehr et al., 2000), although this is dis-
cussed controversially in the literature (Béraud et al., 1999;
Madge and Pober, 2000; Rauch et al., 2000). As serine
phosphorylation of IkBa and degradation of IkBs a and b
were not detected in PC12 and SH-SY5Y cells in response
to NGF, it is conceivable that activation of IkB kinases via
Akt kinase or the Raf/ERK kinase pathway (Nakano et al.,
1998; Nemoto et al., 1998) contributed little to NGF-
induced NF-kB activation in our study. Interestingly, it has
recently been demonstrated that the Raf/ERK pathway
negatively regulates NFkB-dependent gene expression in
cultured fibroblasts (Carter and Hunninghake, 2000), a po-
tential mechanism for the decline in Bcl-xL expression in
cultures treated with higher NGF concentrations.
In summary, our study demonstrates that NGF-induced
NFkB activity and Bcl-xL expression require tyrosine
phosphorylation of IkBa. Activation of NFkB via differ-
ent ligand-receptor systems and downstream signal trans-
duction pathways may enable the nervous system to main-
tain constitutive NFkB activity while responding with an
increased NFkB activity during injury, inflammation, or
repair processes. Moreover, the nonredundancy of NFkB
activation pathways emphasizes the importance of this
transcription factor for neuronal survival.
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